Mantle Cell Lymphoma Insights

This week's must-know community updates, latest research & events

Top Stories

Latest Research

In a case study by Vidal et al. (2025), a 57-year-old male with a history of mantle cell lymphoma (MCL) experienced a recurrence of the disease seven years after initial treatment and remission. The recurrence manifested as a 2 × 3 cm nodule in the right buccal mucosa, which is the inner cheek area. The patient reported symptoms including dysphagia, which is difficulty swallowing, and noted that the nodule had developed rapidly.

Diagnostic efforts included a guided puncture biopsy, which revealed an oval lesion with soft tissue density in contact with the oral mucosa. The differential diagnosis considered the possibility of a salivary gland tumor or a lymphoma recurrence. This case underscores the importance of ongoing vigilance for signs of MCL recurrence, even years after successful treatment.

Clinical Trials

This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-NHL
Study Type
Phase I
Location
United States
Age Range
18+ Years
Enrollment
36
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Study Type
Phase I
Location
United States
Age Range
18+ Years
Enrollment
248
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Study Type
Phase II
Location
United States
Age Range
18+ Years
Enrollment
230
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients with B-cell Malignancies Undergoing Treatment with Bruton Tyrosine Kinase Inhibitors, the HALT Study
Study Type
Observational
Location
Minnesota
Age Range
0 - Not specified
Enrollment
100

Community News

The Leukemia & Lymphoma SocietyThe Leukemia & Lymphoma SocietyMar 18, 2025

Kids deserve better than a one-size-fits-all approach to blood cancer treatment. 🗣️

That’s why The Dare to Dream Project is investing $175 million to transform care with safer, more effective options. From breakthrough clinical trials to vital support services, we’re daring to create a world where kids not only survive but thrive. Learn more 👉 https://bit.ly/4c36qrJ#WeDareToDream4Kids

Lymphoma ActionLymphoma ActionMar 12, 2025

“I remember walking through the corridors to that meeting and suddenly every poster was saying ‘cancer’ on it. Up until that point, I had not been concerned about things, but suddenly I had a sense that I was heading for bad news.

I was told that it looked like I had Hodgkin lymphoma but that they would need to do a biopsy and more blood tests to confirm the diagnosis and stage. Chemotherapy was scheduled for the first week in May, but when the results came back, they said they wanted to bring that forward as the Hodgkin lymphoma was more advanced than they had suspected.

I was told it was stage 4 and that it was in my neck, chest and groin. I had never heard of Hodgkin lymphoma and read the book I was given and then looked online to get as much information about it. I needed to find out what I was facing and was learning about a condition I had never thought of before.” Joel

Joel talks about his experience of diagnosis and treatment of Hodgkin lymphoma, and what life is like for him now: www.lymphoma-action.org.uk/Joel

#Lymphoma#BloodCancer

#HodgkinsLymphoma

Lymphoma Action Post

Upcoming Events

APR
30
Lymphoma Information Days Lymphoma Action • Aylesbury, United Kingdom    In Person
JUN
14
Lymphoma Walk Fundraiser Lymphoma Research Foundation • New York, NY    In Person